PLANTATION, Fla., Aug. 20, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) today announced that it will host a conference call to provide an update on Company activities.
Access information: | |
Date: | Tuesday, August 26, 2014 |
Time: | 4:30 p.m. Eastern daylight time |
Dial-in numbers: | (888) 505-4369 (U.S. and Canada) or (719) 325-2315 |
Conference ID number: | 9126599 |
Live web cast: | www.neurotropebioscience.com, under “Investor Relations” |
The teleconference replay will be available from three hours after completion through September 2, 2014 at (888) 203-1112 (U.S. and Canada) or (719) 457-0820. The replay pass code is 9126599. The archived web cast will be available on the Company’s web site: www.neurotropebioscience.com, under “Investor Relations.”
About Neurotrope
Neurotrope was formed in October 2012 principally to license, develop and commercialize various novel therapeutic and diagnostic technologies developed by the Blanchette Rockefeller NeuroSciences Institute (BRNI). Neurotrope’s pipeline, under its license from BRNI, includes the drug candidate, bryostatin, for the treatment of Alzheimer’s disease and a minimally invasive, diagnostic biomarker analysis system which would assess the presence of Alzheimer’s in patients. A Phase 2a study with bryostatin for the treatment of Alzheimer’s disease is currently being conducted. In addition, Neurotrope has a world-wide, exclusive license agreement with the Icahn School of Medicine at Mount Sinai to utilize its proprietary information and data package for the use of Bryostatin-1 in the treatment of Niemann-Pick Type C Disease, a rare disease, mostly of children who are afflicted with Alzheimers’ disease-like symptoms. Also, as part of its license from BRNI, the Company has the rights to pursue treatments for a number of orphan diseases, including Fragile X Syndrome. The Company’s preclinical and clinical efforts are focused on the development of conventional small molecules that are extraordinarily potent in the activation of the enzyme PKCe, which has been shown to play a central role in the regrowth or repair of nerve tissues, cells or cell products.
Please visit www.neurotropebioscience.com for further information.
For additional information, please contact:
Robert Weinstein
Chief Financial Officer
(914) 295-2765
rweinstein@neurotropebioscience.com
SOURCE Neurotrope, Inc.
Help employers find you! Check out all the jobs and post your resume.
